MX2020000495A - Polinucleotidos encapsulados y metodos de uso. - Google Patents
Polinucleotidos encapsulados y metodos de uso.Info
- Publication number
- MX2020000495A MX2020000495A MX2020000495A MX2020000495A MX2020000495A MX 2020000495 A MX2020000495 A MX 2020000495A MX 2020000495 A MX2020000495 A MX 2020000495A MX 2020000495 A MX2020000495 A MX 2020000495A MX 2020000495 A MX2020000495 A MX 2020000495A
- Authority
- MX
- Mexico
- Prior art keywords
- polynucleotides
- methods
- present disclosure
- replication competent
- encapsulated polynucleotides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32041—Use of virus, viral particle or viral elements as a vector
- C12N2770/32043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762532886P | 2017-07-14 | 2017-07-14 | |
| US201862648651P | 2018-03-27 | 2018-03-27 | |
| PCT/US2018/042136 WO2019014623A1 (en) | 2017-07-14 | 2018-07-13 | Encapsulated polynucleotides and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020000495A true MX2020000495A (es) | 2020-08-20 |
Family
ID=65002120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020000495A MX2020000495A (es) | 2017-07-14 | 2018-07-13 | Polinucleotidos encapsulados y metodos de uso. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200224220A1 (https=) |
| EP (1) | EP3652325A4 (https=) |
| JP (2) | JP2020530778A (https=) |
| KR (1) | KR20200036873A (https=) |
| CN (1) | CN111212914A (https=) |
| AU (1) | AU2018301701A1 (https=) |
| BR (1) | BR112020000839A2 (https=) |
| CA (1) | CA3069821A1 (https=) |
| IL (1) | IL271969A (https=) |
| MX (1) | MX2020000495A (https=) |
| RU (1) | RU2020106730A (https=) |
| SG (1) | SG11202000312UA (https=) |
| WO (1) | WO2019014623A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018306455A1 (en) | 2017-07-26 | 2020-02-27 | Virogin Biotech Canada Ltd | Oncolytic viral vectors and uses thereof |
| TW202545984A (zh) | 2017-08-09 | 2025-12-01 | 美商生物化學醫療公司 | 核酸分子及其用途 |
| MX2020007010A (es) | 2018-01-05 | 2020-12-10 | Ottawa Hospital Res Inst | Vectores modificados de orthopoxvirus. |
| EP3765048B1 (en) * | 2018-03-12 | 2025-08-27 | Mayo Foundation for Medical Education and Research | Using infectious nucleic acid to treat cancer |
| WO2020033863A1 (en) | 2018-08-09 | 2020-02-13 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
| CN113166783B (zh) | 2018-10-09 | 2024-10-11 | 不列颠哥伦比亚大学 | 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法 |
| EP3880812A4 (en) * | 2018-11-13 | 2022-09-07 | Oncorus, Inc. | ENCAPSULATED POLYNUCLEOTIDES AND METHODS OF USE |
| EP3906039A4 (en) * | 2019-01-04 | 2023-01-18 | Oncorus, Inc. | ENCAPSULATED POLYNUCLEOTIDES AND METHODS OF USE |
| JP2022526094A (ja) * | 2019-03-14 | 2022-05-23 | マサチューセッツ インスティテュート オブ テクノロジー | 操作された単純ヘルペスウイルス－１（ｈｓｖ－１）ベクターおよびその使用 |
| CN114514323A (zh) * | 2019-08-05 | 2022-05-17 | 复诺健生物科技加拿大有限公司 | 遗传修饰的肠病毒载体 |
| CA3157063A1 (en) * | 2019-10-10 | 2021-04-15 | Oncorus, Inc. | Dual viruses and dual oncolytic viruses and methods of treatment |
| US20230416308A1 (en) * | 2020-05-29 | 2023-12-28 | Oncorus, Inc. | Encapsulated rna replicons and methods of use |
| BR112022025217A2 (pt) * | 2020-06-11 | 2023-01-03 | Etherna Immunotherapies Nv | Nanopartículas lipídicas |
| US20230242994A1 (en) * | 2020-07-10 | 2023-08-03 | Shanghai Miran Biotech Co., Ltd. | Fluorescent cross-linked rnase h mutant conjugate, mirna combination and application thereof |
| AU2022206676A1 (en) * | 2021-01-06 | 2023-08-24 | Elevatebio Technologies, Inc. | Encapsulated rna polynucleotides and methods of use |
| CN113368261A (zh) * | 2021-06-17 | 2021-09-10 | 苏州大学 | 一种非病毒载体及其制备方法与应用 |
| US20250027107A1 (en) | 2021-10-18 | 2025-01-23 | Flagship Pioneering Innovations Vii, Llc | Dna compositions and related methods |
| TW202409286A (zh) * | 2022-05-20 | 2024-03-01 | 加拿大商復諾健生物科技加拿大有限公司 | 基因組穩定性增強之基因改造腸病毒載體 |
| JP7229412B1 (ja) | 2022-06-14 | 2023-02-27 | キユーピー株式会社 | 脂質ナノ粒子及びその製造方法 |
| CN118634238A (zh) * | 2022-06-27 | 2024-09-13 | 浙江大学 | 抗口腔肿瘤药物活性成分及其用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060026854A (ko) * | 2003-05-28 | 2006-03-24 | 위스콘신 얼럼나이 리서어치 화운데이션 | ＰｏｌⅡ 프로모터 및 리보자임을 갖는 재조합 인플루엔자벡터 |
| WO2005030139A2 (en) * | 2003-09-26 | 2005-04-07 | Novartis Ag | Seneca valley virus based compositions and methods for treating disease |
| US7473418B2 (en) * | 2004-03-25 | 2009-01-06 | Cell Genesys, Inc. | Pan cancer oncolytic vectors and methods of use thereof |
| GB0810912D0 (en) * | 2008-06-13 | 2008-07-23 | Inst Animal Health Ltd | Vector |
| CA2738472A1 (en) * | 2008-09-26 | 2010-04-22 | Tocagen Inc. | Gene therapy vectors and cytosine deaminases |
| CA2782366A1 (en) * | 2009-12-16 | 2011-07-14 | Opko Curna, Llc | Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1 |
| WO2013083753A2 (en) * | 2011-12-07 | 2013-06-13 | Institut Pasteur | Identification of a swine parecho-like virus and applications |
| EP2839015B1 (en) * | 2012-04-18 | 2020-04-29 | Ramot at Tel-Aviv University Ltd. | Lipidated glycosaminoglycan particles for the delivery of nucleic acids |
| JP6396891B2 (ja) * | 2013-04-17 | 2018-09-26 | 新日本製薬株式会社 | 遺伝子改変コクサッキーウイルス |
| US10513711B2 (en) * | 2014-08-13 | 2019-12-24 | Dupont Us Holding, Llc | Genetic targeting in non-conventional yeast using an RNA-guided endonuclease |
| EP3307308A2 (en) * | 2015-06-10 | 2018-04-18 | Hookipa Biotech AG | Hpv vaccines |
| CN108601802A (zh) * | 2015-12-02 | 2018-09-28 | 纪念斯隆-凯特林癌症中心 | 塞尼卡谷病毒（svv）细胞受体靶向的肿瘤治疗 |
-
2018
- 2018-07-13 AU AU2018301701A patent/AU2018301701A1/en not_active Abandoned
- 2018-07-13 MX MX2020000495A patent/MX2020000495A/es unknown
- 2018-07-13 JP JP2020523236A patent/JP2020530778A/ja active Pending
- 2018-07-13 SG SG11202000312UA patent/SG11202000312UA/en unknown
- 2018-07-13 RU RU2020106730A patent/RU2020106730A/ru unknown
- 2018-07-13 EP EP18832967.6A patent/EP3652325A4/en not_active Withdrawn
- 2018-07-13 CA CA3069821A patent/CA3069821A1/en active Pending
- 2018-07-13 WO PCT/US2018/042136 patent/WO2019014623A1/en not_active Ceased
- 2018-07-13 US US16/630,990 patent/US20200224220A1/en not_active Abandoned
- 2018-07-13 BR BR112020000839-7A patent/BR112020000839A2/pt not_active Application Discontinuation
- 2018-07-13 KR KR1020207004226A patent/KR20200036873A/ko not_active Ceased
- 2018-07-13 CN CN201880057021.3A patent/CN111212914A/zh active Pending
-
2020
- 2020-01-12 IL IL271969A patent/IL271969A/en unknown
-
2023
- 2023-09-27 JP JP2023166265A patent/JP2023165916A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020000839A2 (pt) | 2020-07-21 |
| US20200224220A1 (en) | 2020-07-16 |
| RU2020106730A (ru) | 2021-08-16 |
| EP3652325A4 (en) | 2021-09-15 |
| EP3652325A1 (en) | 2020-05-20 |
| CN111212914A (zh) | 2020-05-29 |
| CA3069821A1 (en) | 2019-01-17 |
| IL271969A (en) | 2020-02-27 |
| AU2018301701A1 (en) | 2020-02-27 |
| SG11202000312UA (en) | 2020-02-27 |
| JP2020530778A (ja) | 2020-10-29 |
| KR20200036873A (ko) | 2020-04-07 |
| JP2023165916A (ja) | 2023-11-17 |
| WO2019014623A1 (en) | 2019-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020000495A (es) | Polinucleotidos encapsulados y metodos de uso. | |
| MX2021005448A (es) | Polinucleotidos encapsulados y metodos de uso. | |
| EP4349404A3 (en) | Respiratory virus vaccines | |
| PH12018500855A1 (en) | Herpes simplex virus vaccine | |
| PH12018500856A1 (en) | Respiratory syncytial virus vaccine | |
| EP4501318A3 (en) | Nucleic acid vaccines | |
| WO2015162302A3 (en) | Treatment of hyperbilirubinemia | |
| WO2015168108A3 (en) | Methods for treating cancer using nucleic targeting mdm2 or mycn | |
| WO2018089851A3 (en) | Influenza vaccine | |
| MX2023001394A (es) | Genes del factor viii optimizados. | |
| HK1255192A1 (zh) | 表达细胞因子和羧酸酯酶的修饰的溶瘤痘苗病毒及其使用方法 | |
| PH12016501684A1 (en) | Gene therapy for retinitis pigmentosa | |
| PH12019550113A1 (en) | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus | |
| MX361728B (es) | Ácido nucleico que comprende o codifica un tallo-bucle de histona y una secuencia poli(a) o una señal de poliadenilación para incrementar la expresión de un antígeno tumoral codificado. | |
| MX2018008051A (es) | Variantes de beta-glucanasa y polinucleotidos que las codifican. | |
| MX2016008776A (es) | Proteína de fusión de inhibe angiogénesis o crecimiento y uso de la misma. | |
| WO2018083220A3 (en) | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines | |
| HK1207871A1 (en) | Peptides derived from viral proteins for use as immunogens and dosage reactants | |
| MX2018011980A (es) | 3-epimerasa y polinucleotido que la codifica. | |
| PH12022550282A1 (en) | Viral particles for use in treating synucleinopathies such as parkinson`s diseases by gene therapy | |
| MX2018005872A (es) | Profarmacos de acido nucleico. | |
| NZ603442A (en) | Treatment of proliferative diseases | |
| DK201370530A (en) | Salmonid alphavirus vaccine | |
| ZA201900641B (en) | Viral vaccines | |
| WO2016200113A3 (ko) | 녹차 추출물에 의해 불화된 바이러스를 포함하는 백신 및 그의 제조방법 |